0001179110-13-013915.txt : 20130905 0001179110-13-013915.hdr.sgml : 20130905 20130905194358 ACCESSION NUMBER: 0001179110-13-013915 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130830 FILED AS OF DATE: 20130905 DATE AS OF CHANGE: 20130905 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES INC CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Alton Gregg H CENTRAL INDEX KEY: 0001334682 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 131081561 MAIL ADDRESS: STREET 1: 333 LAKESIDE DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 edgar.xml FORM 4 - X0306 4 2013-08-30 0 0000882095 GILEAD SCIENCES INC GILD 0001334682 Alton Gregg H GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY CA 94404 0 1 0 0 EVP, Corp & Med Affairs Common Stock 2013-08-30 5 G 0 E 1000 0 D 50938 D Common Stock 2013-09-03 4 M 0 26000 16.395 A 76938 D Common Stock 2013-09-03 4 S 0 25100 60.9709 D 51838 D Common Stock 2013-09-03 4 S 0 900 61.5239 D 50938 D Common Stock 2013-09-03 4 S 0 3900 60.9678 D 47038 D Common Stock 2013-09-03 4 S 0 100 61.5191 D 46938 D Non-Qualified Stock Option (right to buy) 16.395 2013-09-03 4 M 0 26000 0 D 2017-01-22 Common Stock 26000 14742 D The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Shares gifted to a donor advised fund. Sale prices reported for the transactions reported here range from $60.41 to $61.40. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Sale prices reported for the transactions reported here range from $61.51 to $61.56. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Sale prices reported for the transactions reported here range from $60.4287 to $61.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. /s/ Gregg H. Alton 2013-09-05